Literature DB >> 22742816

Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.

Erico Masala1, Ana Valencia, Francesca Buchi, Daniele Nosi, Elena Spinelli, Antonella Gozzini, Francesca Sassolini, Alessandro Sanna, Sandra Zecchi, Alberto Bosi, Valeria Santini.   

Abstract

We observed aberrant gene methylation of Wnt antagonists: sFRP1, sFRP2, sFRP4, sFRP5 and DKK1 in marrow cells of 55 MDS cases. Methylation of Wnt antagonist genes was associated with activation of the Wnt signaling pathway, consistent with the up-regulation of the Wnt downstream genes TCF1 and LEF1. Azacitidine exposure induced demethylation of Wnt-antagonist gene promoters and reduction of the non-phosphorylated β-catenin (NPBC) which is prevalent during Wnt pathway inactivation. Presence of ≥5% of bone marrow blasts was associated with methylation of sFRP1 and DKK1 and with methylation of more than two of the five Wnt antagonist genes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22742816     DOI: 10.1016/j.leukres.2012.05.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

2.  Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.

Authors:  Yan-Fung Wong; Chris N Micklem; Masataka Taguchi; Hidehiro Itonaga; Yasushi Sawayama; Daisuke Imanishi; Shinichi Nishikawa; Yasushi Miyazaki; Lars Martin Jakt
Journal:  Stem Cells Transl Med       Date:  2014-08-13       Impact factor: 6.940

Review 3.  Canonical Wnt: a safeguard and threat for erythropoiesis.

Authors:  Rosa A Krimpenfort; Micha Nethe
Journal:  Blood Adv       Date:  2021-09-28

Review 4.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

Review 5.  Myelodysplasia is in the niche: novel concepts and emerging therapies.

Authors:  E Bulycheva; M Rauner; H Medyouf; I Theurl; M Bornhäuser; L C Hofbauer; U Platzbecker
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 6.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

Review 7.  Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.

Authors:  Nicola Stefano Fracchiolla; Bruno Fattizzo; Agostino Cortelezzi
Journal:  Stem Cells Int       Date:  2017-08-21       Impact factor: 5.443

8.  Methylation-reprogrammed Wnt/β-catenin signalling mediated prenatal hypoxia-induced brain injury in foetal and offspring rats.

Authors:  Yingying Zhang; Mengshu Zhang; Lingjun Li; Bin Wei; Axin He; Likui Lu; Xiang Li; Lubo Zhang; Zhice Xu; Miao Sun
Journal:  J Cell Mol Med       Date:  2018-05-28       Impact factor: 5.295

Review 9.  Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives.

Authors:  Megan Wagstaff; Brandon Coke; Georgia R Hodgkiss; Rhys G Morgan
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.